PDCD1 and cancer: Many cancer patients have been under several potential modalities such as chemotherapy, radiotherapy, and cardiotoxic targeted therapy before using PD-1/PDL-1 inhibitors, which lead to amplified cardiotoxic effects and misdiagnosis like Rapidly Accelerated Fibrosarcoma kinase (Raf) and Mitogen-Activated Protein Kinase inhibitors (MEK), anthracyclines, and Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitors.